Azithromycin is generally well tolerated.

Earlier this year, Medico and colleagues reported the results of a pharmacokinetic room of a digit 10 mg/kg intravenous (IV) dose of azithromycin in 32 children between 0.5 and 16 period of age. The ratio extremum assemblage was 2.4 mcg/ml, with an AUC of 8.2 mcg·hr/ml, a quantity of spacing of 44.1 L/kg, a permission of 15.3 ml/min/kg, and an murder half-life of 65.2 hour. Unlike the studies conducted with oral therapy, none of the pharmacokinetic parameters varied significantly with age.
Azithromycin is generally well tolerated. In pediatric clinical trials, the most frequently reported adverse effects were diarrhea (1-6%), abdominal pain (1-4%), sickness (0.5-2%), vomiting (1-6%), worry (1-2%), and rash (0.4-2%). Less common adverse effects included dizziness, excitement, insomnia, temporary state, expectancy, irregularity, loss of appetite, body part pain, and pruritus. Traveler neutropenia was also reported. Discontinuation due to treatmentrelated adverse effects in pediatric clinical trials was approximately 1%.